Surveillance of Efficacy and Tolerability in Von Willebrand's disease

ISRCTN ISRCTN63533506
DOI https://doi.org/10.1186/ISRCTN63533506
Secondary identifying numbers WIL-15
Submission date
18/11/2008
Registration date
19/11/2008
Last edited
07/04/2011
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Haematological Disorders
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Ms Jennifer Feddern
Scientific

Octapharma GmbH
Langenfeld
40764
Germany

Email jennifer.feddern@octapharma.de

Study information

Study designNon-interventional, observational, open, prospective, multi-centre study
Primary study designObservational
Secondary study designMulti-centre
Study setting(s)Hospital
Study typeTreatment
Participant information sheet Not available in web format, please use the contact details below to request a patient information sheet
Scientific title
Study acronymWilate-SET
Study objectivesThe efficacy of Wilate® in clinical practice is comparable to the efficacy in clinical trial patients.

As of 07/05/2011 the anticipated end date for this trial has been extended from 31/07/2009 to 31/07/2012
Ethics approval(s)As the procedures during this observational study do not interfere with the patient's usual treatment and monitoring of treatment, this study is not regarded as a clinical study as defined by EU Directive 2001/20/EC. Therefore approval by an Independent Ethical Committee as an Institutional Review Board is not required.
Health condition(s) or problem(s) studiedVon Willebrand's disease
InterventionDocumentation of details of diagnosis and bleeding frequency at entry, details of bleeding episodes and surgical procedures during 2-year individual observation period. Documentation of details of each injection including assessment of efficacy and tolerability at a 4-point verbal rating scale. Documentation of relevant laboratory assessments if performed.
Intervention typeDrug
Pharmaceutical study type(s)
PhaseNot Specified
Drug / device / biological / vaccine name(s)Wilate®
Primary outcome measurePercentage of efficacy assessments with rating "excellent/good".
Secondary outcome measuresPercentage of tolerability assessments with rating "excellent/good".
Overall study start date01/02/2005
Completion date31/07/2012

Eligibility

Participant type(s)Patient
Age groupOther
SexBoth
Target number of participantsAt least 30 patients
Key inclusion criteriaPatients (any age and gender) suffering from hereditary or acquired Von Willebrand's disease requiring von Willebrand factor (VWF)/coagulation factor eight (FVIII) concentrate.
Key exclusion criteriaDoes not comply with the above inclusion criteria
Date of first enrolment01/02/2005
Date of final enrolment31/07/2012

Locations

Countries of recruitment

  • Germany

Study participating centre

Octapharma GmbH
Langenfeld
40764
Germany

Sponsor information

Octapharma GmbH (Germany)
Industry

Elisabeth-Selbert-Str. 11
Langenfeld
40764
Germany

Email VWS@octapharma.de
ROR logo "ROR" https://ror.org/002k5fe57

Funders

Funder type

Industry

Octapharma GmbH (Germany)

No information available

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan